Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan

• Main Authors: Chia-Chen Hsu (Author), Yu-Bin Pan (Author), Chyong-Huey Lai (Author), Ting-Chang Chang (Author), Lan-Yan Yang (Author), Hung-Hsueh Chou (Author)
• Formato: Livro
• Publicado em: Elsevier, 2021-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: The first Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor, olaparib, was approved by Taiwan Food and Drug Administration in June 2018, which was available under a compassionate use program since 2015. This study aims to report the early experience of the effectiveness and a...